Floatz logo

BEBT 908

Relapsed or Refractory Diffuse Large B-cell Lymphoma

BeBetter Med IncSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Relapsed or Refractory Diffuse Large B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Bebt-908 For
BeBetter Med Inc
Phase 2B
Opb-111077
Otsuka Pharmaceutical Co., Ltd.
Phase 1CC
Tinostamustine
Royal Marsden NHS Foundation Trust
Phase 1CC

Same molecule, other indications

BEBT 908 is also rated in:

acute lymphoblastic leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
Relapsed or Refractory Non-Hodgkin's LymphomaDormant
CC
Indicative ·
47 / 100
View asset →
Relapsed or Refractory Multiple MyelomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →